NRAS and melanoma: Douglas et al. demonstrated that the overall response rate (ORR) in melanoma patients (n = 11) with positive NRAS mutations was significantly higher (64% vs 30%) than those with wildtype NRAS (n = 33) after receiving immunotherapy30.